Agenus Stock Price, News & Analysis

Agenus (NASDAQ: AGEN) reported promising new clinical data for AGEN1181, an Fc-enhanced anti-CTLA-4, at the SITC 36th Annual Meeting. The study showed seventeen objective responses across nine cancer types, including colorectal, ovarian, and melanoma. Notably, four confirmed responses were seen in treatment-refractory tumors. The regimen was well-tolerated, with no high-grade safety issues observed. Phase 2/3 trials will commence in colorectal and gynecological cancers, potentially paving the way for regulatory approvals based on these strong efficacy signals.

Agenus Inc. (NASDAQ: AGEN) reported promising clinical results for AGEN1181, indicating durable responses across 9 cancer types, including those resistant to PD-1 therapy. The company plans to initiate Phase 2/3 trials for AGEN1181 in colorectal and gynecological cancers. Additionally, Agenus withdrew its BLA for balstilimab while launching an expanded access program. Financially, the third quarter showed significant revenue growth, with $275 million reported compared to $57 million in the prior year, alongside a net income of $177 million, up from a loss of $52 million.

Agenus (NASDAQ: AGEN) announced that Dr. Steven O’Day and Dr. Dhan Chand will participate in a fireside chat hosted by B. Riley on November 15, 2021, at 12:00 PM EST. The discussion will focus on the AGEN1181 program, an Fc-enhanced CTLA-4, following the presentation of clinical data at the Society for Immunotherapy of Cancer's 36th Annual Meeting on November 12, 2021. Registration for the webinar is available online, with a replay to be accessible on the company's Events & Presentations page post-call.

Agenus specializes in immuno-oncology with a focus on therapies to combat cancer.

Agenus (NASDAQ: AGEN) announced a webcast featuring Dr. Steven O’Day and Dr. Manuel Hidalgo, discussing updated Phase 1 clinical trial results for AGEN1181, an Fc-enhanced anti-CTLA-4 therapy, and its combination with balstilimab (anti-PD-1). This presentation is scheduled for November 12, 2021, during the SITC 36th Annual Meeting. The event will delve into the significance of the trial data and future development paths. Interested parties can register in advance for the webinar, with a replay available post-event on Agenus’ website.

Agenus (NASDAQ: AGEN) has announced its plan to release third quarter 2021 financial results on November 9, 2021, before the market opens. The company will also hold a conference call at 8:30 a.m. ET on the same day to discuss these results and provide a corporate update. Agenus, based in Lexington, MA, focuses on immuno-oncology therapies aimed at engaging the body’s immune system to combat cancer. Investors can access the live webcast and replay via the company’s website.

Agenus (NASDAQ: AGEN) has voluntarily withdrawn its Biologics License Application (BLA) for balstilimab, following the FDA's recommendation after the early approval of pembrolizumab. The BLA for balstilimab had received Fast Track and Priority Review status and was scheduled for action on Dec. 16, 2021. Balstilimab demonstrated a 20% response rate in PD-L1 positive patients during trials, outperforming pembrolizumab's 14%. Agenus plans to launch expanded access programs for balstilimab and will discontinue its BRAVA trial, potentially saving over $100M in R&D expenses.

Agenus (NASDAQ: AGEN) has announced the triggering of a $20 million milestone payment from Bristol Myers Squibb following the first patient dosing in the Phase 1 study of AGEN1777, a bispecific anti-TIGIT antibody. This agreement includes a total of $200 million upfront and up to $1.36 billion in additional milestones. AGEN1777 aims to enhance immune response against cancers, particularly targeting difficult tumors like non-small cell lung cancer. The trial's focus on safety and tolerability will help set the recommended Phase 2 dose.

Agenus Inc (NASDAQ: AGEN) announced the acceptance of an abstract detailing updated Phase 1 clinical trial results for AGEN1181, an Fc-enhanced anti-CTLA-4, alone and in combination with balstilimab (anti-PD-1). This will be presented at the Society for Immunotherapy of Cancer's 36th Annual Meeting, scheduled for November 10-14, 2021. The presentation aims to enhance understanding of AGEN1181's efficacy in treating advanced solid tumors. The full abstract will be accessible on November 9, 2021, in the investor section of their website.

Agenus (NASDAQ: AGEN) presented final results from a Phase 2 study on the Bal/Zal combination therapy for recurrent/metastatic cervical cancer at the ESMO Virtual Conference. With a median follow-up of 19.4 months, the objective response rate was 26%, including 9% complete responses. The combination exhibited improved responses across histology subgroups, including those previously unresponsive to therapies. No unexpected toxicities were observed, and further data on AGEN1181 is anticipated later this year.